Ameritas Advisory Services’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.55K Sell
99
-4,866
-98% -$253K ﹤0.01% 1555
2026
Q1
$238K Sell
4,965
-436
-8% -$19.1K 0.01% 862
2025
Q4
$209K Buy
+5,401
New +$206K 0.01% 889
2025
Q3
Sell
-7
Closed -$252 2768
2025
Q2
$252 Buy
+7
New +$232 ﹤0.01% 2740
2023
Q2
Sell
-410
Closed -$14.8K 2128
2023
Q1
$14.8K Buy
+410
New +$15.2K ﹤0.01% 1763

Other funds holding RPRX

Ameritas Advisory Services's RPRX Position: Q2 2026 in Review

Ameritas Advisory Services reduced its Royalty Pharma (RPRX) stake by 98% in Q2 2026, selling an estimated $253K and leaving 99 shares worth $5.55K. The position accounts for ﹤0.01% of the portfolio, ranked #1555.

Ameritas Advisory Services first reported a position in RPRX in Q1 2023 and has held it in 5 quarters since. The position peaked at $238K in Q1 2026. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Ameritas Advisory Services held 99 shares of Royalty Pharma worth $5.55K as of Q2 2026.
  • Ameritas Advisory Services sold 4,866 Royalty Pharma shares in Q2 2026, an estimated $253K.
  • Royalty Pharma made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q2 2026, its #1555 holding.
  • Ameritas Advisory Services first reported a position in Royalty Pharma in Q1 2023 and has held it in 5 quarters since.
  • Ameritas Advisory Services's Royalty Pharma position peaked at $238K in Q1 2026.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.